Your browser doesn't support javascript.
loading
Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers.
Bon, Giulia; Loria, Rossella; Amoreo, Carla Azzurra; Verdina, Alessandra; Sperduti, Isabella; Mastrofrancesco, Arianna; Soddu, Silvia; Diodoro, Maria Grazia; Mottolese, Marcella; Todaro, Matilde; Stassi, Giorgio; Milella, Michele; De Maria, Ruggero; Falcioni, Rita.
  • Bon G; Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Loria R; Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Amoreo CA; Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Verdina A; Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Sperduti I; Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Mastrofrancesco A; Physiopathology Laboratory of Skin, IRCCS San Gallicano Dermatological Institute, Rome, Italy.
  • Soddu S; Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Diodoro MG; Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Mottolese M; Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Todaro M; Surgical and Oncological Sciences, University of Palermo, Palermo, Italy.
  • Stassi G; Surgical and Oncological Sciences, University of Palermo, Palermo, Italy.
  • Milella M; Department of Experimental Clinical Oncology, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • De Maria R; General Pathology, Catholic University of Rome, Rome, Italy.
  • Falcioni R; Department of Research, Advanced Diagnostic, and Technological Innovation, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Oncotarget ; 8(65): 108463-108479, 2017 Dec 12.
Article en En | MEDLINE | ID: mdl-29312543